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Type III secretion (TTS) is an essential virulence function for
Shigella flexneri that delivers effector proteins that are respon-
sible for bacterial invasion of intestinal epithelial cells. The Shi-
gella TTS apparatus (TTSA) consists of a basal body that spans
the bacterial inner and outer membranes and a needle exposed
at the pathogen surface. At the distal end of the needle is a “tip
complex” composed of invasion plasmid antigenD (IpaD). IpaD
not only regulates TTS, but is required for the recruitment and
stable association of the translocator protein IpaB at the TTSA
needle tip in the presence of deoxycholate or other bile salts.
This phenomenon is not accompanied by induction of TTS or
the recruitment of IpaC to the Shigella surface. We now show
that IpaD specifically binds fluorescein-labeled deoxycholate
and, based on energy transfer measurements and docking sim-
ulations, this interaction appears to occur where theN-terminal
domain of IpaD meets its central coiled-coil, a region that may
also be involved in needle-tip interactions. TTS is initiated as a
series of distinct steps and that small molecules present in the
bacterial milieu are capable of inducing the first step of TSS
through interactions with the needle tip protein IpaD. Further-
more, the amino acids proposed to be important for deoxy-
cholate binding by IpaD appear to have significant roles in reg-
ulating tip complex composition and pathogen entry into host
cells.
Shigella flexneri is the etiologic agent of shigellosis, a poten-
tially life-threatening bacillary dysentery in humans. Although
shigellosis is typically considered a disease of the developing
world, it is an underreported problem in industrialized nations
where it is an infectious agent in child daycare centers, nursing
homes, and in any situation where sanitation procedures
become compromised (1). Shigellosis is spread by the fecal-oral
route with larger outbreaks linked to contaminated water,
whichmakes it a serious public health problem anywhere treat-
ment regimens are inadequate. Following ingestion, Shigella
travels to the colon where it crosses M cells and kills macro-
phages to gain access to the basal side of the colonic epithelium.
S. flexneri then promotes its own uptake into epithelial cells by
inducing membrane ruffling at the site of pathogen contact.
Shigella invasiveness is the product of a 31-kb segment on its
large virulence plasmid, which encodes the components of a
type III secretion system (TTSS).4 The Shigella TTSS is used to
subvert the normal host cell mechanisms that control the actin
cytoskeleton to promote invasion (2, 3). Within this genetic
region, themxi/spa operons encode the type III secretion appa-
ratus (TTSA) and the ipa/ipg operon encodes the type III
secreted protein effectors/translocators, IpaA-D, and IpgC, the
cytoplasmic chaperone for IpaB and IpaC (4). The TTSA is a
nanomachine that provides a conduit for secretion from the
bacterial cytoplasm to the membrane and cytoplasm of target
cells. It is composed of two main parts: an external needle that
allows host cell contact and a basal body that traverses the bac-
terial inner and outer membranes and cell wall and is in many
respects similar to the flagellar basal body (5, 6). In S. flexneri
the exposed needle is a homopolymer of MxiH that is 45 nm
in length, 7.0 nm in diameter, and with a central channel that is
about 2.5 nm in diameter (7). Of the TTSS-secreted proteins,
the three translocators, IpaB, IpaC, and IpaD, are essential for
invasion (8).
We recently showed that IpaD resides at the tip of the S.
flexneri TTSA needle (9). IpaD has an overall dumbbell-shape
with an intramolecular coiled-coil providing the handle (10).
IpaD most likely resides at the needle tip with its N-terminal
globular domain and the C-terminal tail near the needle tip and
the second globular domain positioned away from the needle
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(10, 11). The C-terminal end of IpaD, which contributes to for-
mation of one of the stabilizing coiled-coil helices, appears to be
involved with anchoring it at the tip of the MxiH needle (9).
When S. flexneri is grown in tryptic soy broth (TSB), IpaD is the
only Ipa protein found exposed at the tip of the needle (9).
When the bacteria are grown in the presence of the bile salt
deoxycholate, however, IpaB is recruited to the needle tip to
form a ternary complex consisting of MxiH, IpaD, and IpaB
(11). This step may serve to prepare the S. flexneri TTSA for
host cell contact because it is IpaB that has been shown to bind
to the host cell components involved in the entry process
(12–14).
Bile salts have been implicated as agents that modulate the
virulence capacity of S. flexneri (15). Although they are not
inducers of type III secretion (11), bile salts do increase the
adherence and invasion properties of S. flexneri (15). Here we
present experimental and computational evidence that deoxy-
cholate binds directly to IpaD at a position that may be at the
interface between IpaD andMxiH at the needle tip. This infor-
mationwill be of value in the rational design of compounds that
may block known steps inTTSAneedle tipmaturation and thus
serve as TTSS-specific anti-infective agents.
EXPERIMENTAL PROCEDURES
Materials—Antibodies to IpaB, IpaC, and IpaD were pro-
vided by E. V. Oaks (Walter Reed Army Institute for Research,
Silver Spring, MD). The S. flexneri ipaD null strain (SF622) was
from P. J. Sansonetti (Institute Pasteur, Paris, France) and
grown at 37 °C on trypticase soy agar containing 0.025% Congo
red to ensure the selection of bacteria harboring the virulence
plasmid. Fluorescent probes andAlexa Fluor-labeled secondary
antibodies were from Invitrogen. Escherichia coli Tuner(DE3),
E. coli NovaBlue, pET15b, and ligation reagents were from
Novagen (Madison, WI). Restriction enzymes were from New
England BioLabs (Tozer, MA). Oligonucleotide primers were
from IDT (Coralville, IA). IMAC affinity resin was from Sigma.
Other chemicals were reagent grade.
Growth of S. flexneri in the Presence of Deoxycholate—S. flex-
neri is routinely grown to early or mid log phase in TSB after
inoculation from a trypticase soy agar plate containing Congo
red. These growth conditions do not lead to detectable levels of
IpaB on the bacterial surface. To inducemobilization of IpaB to
the needle tip, the S. flexneri was grown for 30 min in TSB
containing 2.5 mM (0.1%, w/v) deoxycholate. None of the con-
ditions used here promoted the recruitment of IpaC to the Shi-
gella surface or led to induction of type III secretion (data not
shown).
Immunofluoresence Microscopy—S. flexneri were grown to
early log phase in TSB with or without 2.5 mM deoxycholate.
Bacteria were collected by centrifugation, washed twice with
PBS, and resuspended in 4% (v/v) formaldehyde in 10mMphos-
phate, pH 7.2, 150 mM NaCl (phosphate-buffered saline). The
bacteria were fixed to slides and blocked with 1% bovine serum
albumin in PBS. IpaD was detected using monoclonal mouse
anti-IpaD antibodies and Alexa Fluor 488 goat anti-mouse IgG.
IpaB was detected using rabbit anti-IpaB antiserum and Alexa
Fluor 568 goat anti-rabbit IgG. Imaging was performed using a
Yokugawa-type spinning disk confocal attached to anOlympus
IX-81 microscope, alternately using either the 473-nm laser
line with a 505–530 band-pass emission filter (Alexa 488) or a
561-nm laser line with a 580–520 band-pass emission filter
(Alexa 568). Transmission imageswere also obtained. To deter-
mine the importance of IpaD-bile salt interactions on the pres-
ence of IpaD and IpaB on the bacterial surface, mutations were
introduced into IpaD and the number of bacteria labeled with
anti-IpaD and/or anti-IpaB antibodies was determined. Multi-
ple fields (n  10) were viewed following fluorescence labeling
and the number of bacteria with IpaD on their surface was
counted as a function of total bacteria in the field. The samewas
then done for IpaB. Greater than 90% of bacteria with a given
protein on their surfaces was considered positive (), whereas
fewer than 5%of the bacteriawith the protein of interest labeled
on their surfaces was considered negative () for the presence
of that protein.
Preparation of FITC-Deoxycholate—The three-step synthe-
sis of fluorescein 4-isothiocyanate-labeled deoxycholate (FITC-
deoxycholate, 4) is shown in Fig. 1. Additional experimental
details for each step and the spectral data are given under sup-
plementaryMaterials. FITC-deoxycholate 4 is prepared by first
converting deoxycholic acid (1) into a hexylamino amide 3 by
treatment of a N,N-dimethylformamide solution of 1 with
hydroxybenzotriazole and 1-ethyl-3-(3-dimethyl aminopro-
pyl)carbodiimide hydrochloride followed by addition of tert-
butyl 6-aminohexylcarbamate. After stirring for 22 h at room
temperature, the solution was diluted with ethyl acetate,
extracted with water, and the organic phase dried with anhy-
drous magnesium sulfate. The solvent was removed under vac-
uum and 15 ml of 4 M HCl in 1,4-dioxane was added and the
solution stirred for 1 h. Removal of the solvent under reduced
pressure gave awhite precipitate of the trifluoroacetate salt of3.
The salt (3) wasmixedwith FITC inmethanol and stirred for 30
min to dissolve the reactants. Triethylamine was then slowly
added and the reaction mixture stirred for an additional 16 h.
The solvent was then removed under reduced pressure to yield
a reddish brown precipitate that was purified by flash column
chromatography to give a yellowish waxy precipitate of fluores-
cein 4-isothiocyanate-labeled deoxycholate (FITC-deoxy-
cholate, 4) as shown in Fig. 1. The structure of 4was confirmed
by mass spectrometry (see supplemental materials Fig. S1).
Protein Expression and Purification—Recombinant IpaD,
SipD, and BipD have been prepared by standard methods as
previously described (16, 17). Briefly, Tuner(DE3) containing
D/pET15b, SipD/pET15b, or BipD/pET15b were grown to 0.5
A600 units, induced to express protein with 1.0 mM isopropyl
1-thio--D-galactopyranoside and incubated a further 3 h. The
bacteria were collected by centrifugation, lysed by sonication,
and theHisTag protein from the clarified supernatantwas puri-
fied by standard nickel affinity chromatography.
For fluorescence spectroscopic analysis, IpaD was labeled
with 7-diethylamino-3-(4-maleimidylphenyl)-4-methylcou-
marin (CPM) at its single Cys residue (Cys-322). Briefly, IpaD at
2 mg/ml in PBS was diluted with an equal volume of N,N-di-
methylformamide. CPM was added from a stock solution pre-
pared in N,N-dimethylformamide to give a final concentration
of 2 mM and the mixture was incubated for at least 1 h on ice.
Any precipitate that formedwas removed by centrifugation and
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the labeled protein was separated from free dye by gel filtration
using a Sephadex G-50 column equilibrated with PBS.
Fluorescence Polarization—The interaction of IpaD with
FITC-deoxycholate was measured using fluorescence polariza-
tion (FP) spectroscopy (18). FP provides a measure of the rota-
tional diffusion of a fluorescent molecule in solution. The asso-
ciation of the small fluorescent FITC-deoxycholate with a
larger nonfluorescent partner like IpaD results in an increase in
themolecular volumeof the fluorescent species, thus giving rise
to an increased mP value. FP measurements for FITC-deoxy-
cholate were obtained using a Beacon fluorescence polarimeter
(Panvera Corp.) as described (18). Briefly, a constant concen-
tration of FITC-deoxycholate (30–50 nM) in PBS was mixed
with increasing concentrations of IpaD (micromolar range).
The change in FP was monitored as a change in millipolariza-
tion units (mP). The ability for non-fluorescent bile salts or
their derivatives to compete for FITC-deoxycholate binding to
IpaD was tested using unlabeled sodium salts of deoxy-
cholate, cholate hydrate, taurodeoxycholate, chenodeoxy-
cholate, and dehydrocholate. A negative control used here
was CAPS buffered to neutral pH. In these experiments,
IpaD (5 M) was simultaneously incubated with 30 nM FITC-
deoxycholate and increasing concentrations of the nonfluo-
rescent competitor for 1 h. At this point, the mP value of the
FITC-deoxycholate was determined and plotted as a func-
tion of competitor concentration.
Förster Resonance Energy Transfer (FRET) Analyses—FRET
measurements were obtained for CPM-labeled IpaD or CPM-
IpaD (donor) and FITC-deoxycholate (acceptor). CPM-IpaD
was used at a final concentration of 50 nM and increasing con-
centrations of either deoxycholate (to give Fd in which the
CPM-IpaD donor is associated with nonfluorescent ligand) or
FITC-deoxycholate (to give Fda inwhich theCPM-IpaD is asso-
ciated with FITC-deoxycholate acceptor). Fluorescence emis-
sionwas scanned from 400 to 520 nmusing an excitation of 385
nm, which allowed for monitoring changes in coumarin emis-
sion upon addition of deoxycholate or FITC-deoxycholate. For
each concentration of ligand, the energy transfer efficiency was
determined according to E  1  Fda/Fd (Equation 1). The Fd
term involved the use of nonfluorescent deoxycholate to
account for possible changes in coumarin emission that might
occur upon ligand binding, however, no change in CPM-IpaD
emission was observed upon the addition of deoxycholate (data
not shown).AROvalue (the theoretical distance thatwould give
50% energy transfer efficiency) was determined to be 52 Å (19),
which was used with the calculated energy transfer maximum
to determine the distance between the coumarin on Cys-322 of
CPM-IpaD to the fluorescein on FITC-deoxycholate according
to E  RO6/(RO6  R6) (Equation 2), where R is the calculated
distance separating the donor and acceptor fluorophores (20).
In determining the RO value, the relative orientation of donor
and acceptor dipoles was assumed to be random (2  2/3).
Although this assumption can introduce potential error to the
measurement of an absolute distance (21), the error introduced
is typically minimal (not more than about 10%) (22) and this is
not expected to distract from the localization of IpaD’s deoxy-
cholate binding site as described here.
MolecularModeling—Structures of all ligands were sketched
in SYBYL (23) andwere optimized to default levels of structural
convergence via Tripos Molecular Force Field (24) and
Gasteiger-Marsili electrostatics (25). Receptor structures were
imported into SYBYL from their native PDB format (i.e. 1HGU
in the case of IpaD (26)). These structureswere then protonated
in SYBYL, crystallographic waters were removed, and
Gasteiger-Marsili were added to all atoms. All Asp and Glu
residues were assumed to be anionic, whereas Lys and Arg res-
idues were rendered as cations. One hundred docked com-
plexes for each ligand-receptor pair were then generated via
AutoDock (27) using the Lamarckian Genetic Algorithm
search protocol (ligand torsional, positional, and rotational
coordinates all varied; receptor held fixed) according to default
settings. Results were then parsed according to clustering tech-
niques provided within the AutoDock suite, and themost plau-
sible complex structure was considered to be the lowest free
energy structure (as quantified by the native AutoDock score
function) of the dominant cluster.
Preparation of ipaD Mutants for Expression in S. flexneri
SF622 or E. coli—D/pwpsf4 containing the ipaD gene has been
described (28). ipaDmutants were made by inverse PCR using
D/pwpsf4 as template, a primer composed of GAGAGA, a
restriction site, and 18 nucleotides flanking the nucleotides to
bemutated and a primer going the opposite direction encoding
GAGAGA, a restriction site, and 18 nucleotides (28). The prim-
ers used to introduce mutations into D/pwpsf4 are given in
supplemental materials Table S1. The resulting PCR products
were digested with the appropriate restriction enzyme,
intramolecularly ligated, and used to transform E. coli Nova-
Blue. Each plasmid was electroporated into S. flexneri SF622.
Ampicillin selection ensured the presence of the ipaD-express-
ing plasmid and kanamycin resistancewith Congo red differen-
tiation ensured that the Shigella virulence plasmid was present.
To produce recombinant mutant IpaD protein, mutant ipaD
genes were subcloned into pET15b as previously described (29,
30). The resulting plasmidswere used to transformTuner(DE3)
cells and the recombinant protein purified as described above.
Gentamycin Protection Assay—Newly designed SF622
strains expressingmutant forms of ipaDwere assessed for their
ability to invade Henle 407 cells by a standard gentamycin pro-
tection assay as previously described (18, 28) with one minor
modification. In previous use of this assay, bacterial-host cell
contact was facilitated by centrifugation, however, this step
was found to interfere with assessing subtle differences in
the invasion capacity of these strains. Therefore, the centrif-
ugation step normally used for monitoring Shigella invasive-
ness was omitted.
RESULTS
Deoxycholate-induced Recruitment of IpaB to the Shigella
Surface Appears to Correlate with Deoxycholate Binding by
IpaD—Wehave previously shown that S. flexneri grown to early
log phase in TSB has IpaD present on its surface. This popula-
tion of IpaD is located at the tip of TTSA needles (11, 29),
presumably due to direct interaction between IpaD and MxiH
(11, 31). IpaB and IpaC were not observed on the surface of
these bacteria.When 2.5 mM deoxycholate was included in this
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growth medium, however, IpaB (but not IpaC) was seen on the
bacterial surface (11). This new population of IpaB was associ-
ated with IpaD at the tip of the TTSA needle (11) (see supple-
mental materials Fig. S2). The same result was achieved for S.
flexneri grown to early log phase and then exposed to chenode-
oxycholate or taurodeoxycholate (11). Furthermore, deoxy-
cholate triggered IpaB surface localization at micromolar con-
centrations (data not shown).
To determine whether the observed deoxycholate effects are
due to bile salt recognition by IpaD, a fluorescent derivative of
deoxycholate was synthesized so that the IpaD-deoxycholate
interaction could be monitored in vitro by fluorescence spec-
troscopic methods. Previously, Mills et al. (32) derivatized
cholate and other bile salts (33, 34) at the single available car-
boxyl group with fluorescein using a lysine linker. These fluo-
rescent bile salt derivativeswere found tomaintain native prop-
erties such as lecithin solubilization, hepatic uptake, biliary
secretion, and stimulation of biliary lipid secretion (32–36).
Similarly, we labeled deoxycholate on the carboxyl group via an
amide linkage with the -amino group of boc-1,6-diaminohex-
ane. After deprotection, the resulting primary amine was
labeled with FITC (Fig. 1 and supplementary materials). S. flex-
neri was then grown in TSB containing FITC-deoxycholate to
determine whether the addition of the tether and fluorophore
affected the biological activity of the deoxycholate. FITC-de-
oxycholate was able to induce the mobilization of IpaB to the
needle tip complex at the same micromolar concentrations as
deoxycholate alone (data not shown).
Using FITC-deoxycholate as a ligand, FP was used to deter-
mine whether deoxycholate directly interacts with IpaD. FP
measures the rate of molecular rotation for a fluorescent mol-
ecule in solution (see “Experimental Procedures”). Small mole-
cules rotate faster in solution, thus giving low polarization val-
ues, whereas larger molecules rotate slower, resulting in higher
polarizations. The increase in size seen when a small fluores-
centmolecule binds to a larger nonfluorescentmoiety gives rise
to a characteristic increase in polarization. The initial polariza-
tion value (in mP units) for FITC-deoxycholate was 27.5 mP.
This small value was expected based on the size of FITC-deoxy-
cholate and the flexibility of the chosen hexyl tether. When
FITC-deoxycholate associates with IpaD and SipD, the IpaD
homologue from Salmonella typhimurium, an increase in mP
was seen. The maximum increase for FITC-deoxycholate with
IpaD was about 250 mP units with an apparent dissociation
constant (kd) in the micromolar range (varying between 5 and
15 M). With SipD, FITC-deoxycholate had a maximum
increase of about 160 mP with a larger apparent kd (see Fig. 2).
In contrast, the putative needle tip protein from Burkholderia
pseudomallei BipD did not give rise to an increase in FITC-
deoxycholate polarization. The negative control in these exper-
iments was IpgC, the cytoplasmic chaperone for IpaB and IpaC
(Fig. 2). These findings link the ability for deoxycholate to
induce in vivo changes in S. flexneri with its ability to bind to
IpaD in vitro.
When different nonfluorescent bile salts or bile salt deriva-
tives were tested for the ability to compete with FITC-deoxy-
cholate for binding to IpaD, deoxycholatewas themost efficient
competitor, however, cholate hydrate, taurodeoxycholate, and
chenodeoxycholate also competedwith FITC-deoxycholate for
binding to IpaD (Fig. 3). In contrast, dehydrocholate was not
found to be competitive for FITC-deoxycholate binding (Fig. 3)
and it failed to promote IpaB recruitment to the Shigella surface
(data not shown). This suggests that placement of functional
groups on these bile salt derivatives may have a role in contrib-
uting to their recognition by IpaD.
Localization of the IpaD Region That Binds Deoxycholate
Based on FRETMeasurements—To provide a starting point for
identifying the deoxycholate binding pocket on IpaD, FRET
(nonradiative) was carried out using a coumarin (CPM) donor
covalently linked to Cys-322 of IpaD and the fluorescein accep-
tor attached to FITC-deoxycholate. To estimate maximum
FRET efficiency, CPM-labeled IpaD was titrated with increas-
ing concentrations of FITC-deoxycholate (data not shown).
Based on these findings, FITC-deoxycholate appeared to bind
FIGURE 1. Synthesis of FITC-deoxycholate (4). A schematic of the synthetic
sequence for labeling deoxycholic acid (1) with FITC through a 1,6-hex-
anediamine tether, 2, 3, is shown. The synthetic details and the MS analysis of
the final FITC-deoxycholate product 4 are given under supplemental Materi-
als and Fig. S1.
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FIGURE 2. FITC-deoxycholate binds to IpaD. FITC-deoxycholate (30 nM)
incubated with nonfluorescent IpaD (closed circles), SipD (open circles), BipD
(closed triangles), and IpgC (open triangles). IpgC is a Shigella cytoplasmic
chaperone that was used here as a negative control for FITC-deoxycholate
binding. The starting mP for FITC-deoxycholate is 27.5. For IpaD binding the
apparent mPmax is 248 and the apparent kd is in the micromolar range
between about 5 to 15 M.
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to full-length IpaD with a low micromolar kd to give a theoret-
ical maximum FRET efficiency of 78%, suggesting that the two
probes are relatively close to one another. Using approximately
a 30-fold excess of FITC-deoxycholate, the level of energy
transfer efficiency can be seen in the typical FRET spectrum
shown in Fig. 4. In all of these experiments, the concentration of
FITC-deoxycholate was kept as low as possible to avoid arti-
facts that could be introduced by a fluorescein-dependent inner
filter affect. An RO value of 52 Å was determined here, which is
largely in agreement with coumarin to fluorescein distances
determined previously (19) and for standard RO values pub-
lished elsewhere (37). These calculations assume a random ori-
entation for the component dipoles, which is reasonable con-
sidering the nature of the tether linking FITC to deoxycholate.
Ultimately, the observed 78% energy transfer efficiency trans-
lates to a distance of 42.1 Å (about 5 Å) from the coumarin
probe to the fluorescein moiety on deoxycholate. Based on the
published crystal structure of IpaD, this places the binding site
of the FITC-deoxycholate near the midpoint of the central
coiled-coil of IpaD.
Molecular Modeling Tentatively Defines the Composition of
the Deoxycholate Binding Site—Although the FRET provides a
tentative distancemeasurement from the Cys-322 of the FITC-
deoxycholate binding site, it does not provide details on the
amino acid residues involved in the binding event. Therefore,
computational analyses were used to dock deoxycholate onto
the published crystal structure of IpaD to determine whether a
tentative binding pocket for this bile salt could be identified. As
shown in Fig. 5, the consensus binding site for deoxycholate on
IpaD is at a site on the stabilizing coiled-coil of the protein
where it interacts with theN-terminal helix-turn-helix globular
domain. This position is consistent with the FRET data pre-
sented above. Docking simulations using full-length IpaD
implicate residues within the central coiled-coil of the protein
(e.g. Ser-158) in deoxycholate binding, as well as N-terminal
domain residues like Leu-75. Docking analyses using FITC-de-
oxycholate as the ligand suggest that it also binds at this site in
the same way as deoxycholate (not shown). Furthermore, addi-
tional docking simulations suggested thatwhile the IpaDN-ter-
minal domainmay contribute to deoxycholate binding, it is not
essential for this event because docking could also be accom-
plished using a truncated form of IpaD (IpaD1–120) and FP
analyses using recombinant IpaD1–120 showed that this pro-
tein was still able to bind FITC-deoxycholate (data not shown).
The identification of a putative deoxycholate binding site on
IpaD now provides the basis for conducting molecular analyses
to confirm whether this is indeed an important functional site
within IpaD.
FIGURE 3. Competition for FITC-deoxycholate binding to IpaD by non-
fluorescent molecules. The ability for nonfluorescent deoxycholate (open
circles), cholate hydrate (closed circles) chenodeoxycholate (open squares),
taurodeoxycholate (closed squares), and dehydrocholate (open triangles). The
negative control used here was CAPS (closed triangles) as described under
“Experimental Procedures.” All of these compounds were used below their
recognized critical micelle concentrations.
FIGURE 4. Determining the distance from the coumarin from CPM-Cys-
322 to the fluorescein of FITC-deoxycholate. FRET from the donor CPM-
Cys-322 residue of IpaD (30 nM) to the acceptor fluorescein on FITC-deoxy-
cholate (in a 30-fold or more excess of acceptor) is seen in the fluorescence
emission spectrum depicted by the dashed line. The same conditions
using deoxycholate that was not labeled with FITC is shown by the solid
line. In this particular experiment, nearly 70% energy transfer efficiency
was observed, however, titration experiments were used to determine
that the maximum energy transfer from the CPM to FITC probes is 78%.
The data shown are from a representative experiment that was performed
six times.
FIGURE 5. Simulated docking of deoxycholate onto the crystal structure
of IpaD is shown. A, deoxycholate docked onto the ribbon structure of IpaD.
B, enlarged version of the binding pocket showing key contacts. Structures of
all ligands were sketched in SYBYL and the protein was imported into SYBYL
from its native PDB format. One hundred docked complexes for each ligand-
receptor pair were generated via AutoDock as described under “Experimen-
tal Procedures.”
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Mutagenesis of the IpaD Residues Suggested to Interact with
Deoxycholate in Docking Analyses—To explore the role of the
IpaD residues predicted to be involved in deoxycholate binding,
site-directed mutagenesis was employed as a means to probe
howmutationsmight alter bile salt bindingwith IpaDand influ-
ence the function of IpaD in host cell invasion.Not surprisingly,
mutation of residues within the N-terminal domain of IpaD
that might interact with deoxycholate (e.g. residues Lys-72,
Leu-75, or Ala-79), do not have an obvious effect on the inva-
sion function of IpaD (Table 1). Because the N-terminal
domain (here considered to be residues 31–120) is not required
for IpaB recruitment to the bacterial surface upon addition of
deoxycholate, these residues were not expected to have amajor
role in deoxycholate-induced events (data not shown). This
finding is also consistent with the modeling and FP results
described above that show that the N-terminal domain is not
required for the docking of deoxycholate onto IpaD in silico or
for the binding of FITC-deoxycholate in vitro. Furthermore, a
recently proposed model of the IpaD-MxiH interaction by
Zhang et al. (31) suggested that the IpaD N terminus may be
displaced by a MxiH unit upon needle tip complex formation,
thus minimizing the role of the N-terminal domain of IpaD in
the function of this protein at the needle tip in vivo. In contrast,
mutation of residues predicted to be involved in deoxycholate
binding based on docking simulations and that are part of the
central coiled-coil of IpaD can have a significant effect on the
ability of IpaD to direct the invasion of cultured epithelial cells
(Table 1). In particular, conversion of Ser-158 to Ala (S158A)
reduced invasiveness by 80% (Table 1). Combinations of muta-
tions with S158A did not result in a further reduction of inva-
siveness, suggesting that Ser-158 alone among these particular
residues has an important role in IpaD function.
It is noteworthy that mutation of Lys-151 to Glu (K151E)
resulted in greater than a 4-fold increase in Shigella invasive-
ness (Table 1). When the crystal structure of IpaD was origi-
nally reported (10) it was suggested that within the context of
the TTSA needle tip complex, IpaD could potentially form a
pentamer with Lys-151 of one monomer forming a salt bridge
with Glu-229 on the adjacent monomer. To test whether dis-
ruption of such a salt bridge could account for this change in
IpaD function, the double mutant IpaDK151E/E229K was gener-
ated to restore any potential salt bridge and thereby restore the
wild-type invasion phenotype to the ipaD null strain S. flexneri
SF622. Instead, the double mutation completely eliminated the
ability of IpaD to restore invasiveness to SF622 (Table 1).Oddly,
the single mutant, IpaDE229K in SF622 led to a 40% reduction in
invasiveness (Table 1). Although this is a significant reduction,
it does not account for the phenotype of IpaDK151E/E229K. These
results suggest that Lys-151 and Glu-229 work together in con-
trolling IpaD function by a mechanism that will need further
examination.
Critical to invasion, and thus the virulence process, is the
ability of IpaD to localize to the TTSA needle tip and recruit
IpaB to the surface after an appropriate signal is detected.
Therefore, immunofluorescence microscopy was used to cor-
relate the impact of the IpaD mutations on invasion (Table 1)
with proper Shigella surface localization of IpaD and IpaB. As
previously demonstrated IpaB staining was not seen on the sur-
face of Shigella prior to deoxycholate addition, whereas IpaD
staining was seen on the surface (Table 2). After deoxycholate
addition, increased IpaD staining was observed and all the cells
had IpaB on their surfaces. In contrast, no IpaD or IpaB are
found on the surface of the ipaD null strain SF622 under any
conditions tested. IpaDS158A had IpaD on its surface in the
absence or presence of deoxycholate, but did have a slight
reduction in the ability to surface localize IpaB when compared
with wild-type levels (Table 2). Although this decrease may not
entirely account for the decrease in the invasion of IpaDS158A, it
could significantly contribute to it if the strain is unable to
mobilize the first pore translocator efficiently. Despite the
greatly elevated invasiveness seen for Shigella making
TABLE 1
The effect of directed IpaD mutations on Shigella invasiveness
IpaD mutant Relative invasiona
ipaD null strain (SF622) 0  0
Wild-type 100  8
K72A 81  10
L75S/A79S 90  19
K72A/L75S/A79S 82  15
E154A/H155A 104  15
S158A 22  4b
E154A/H155A/S158A 21  9b
S158A/T161A 28  5b
S158A/Q162A 18  1b
K151E 421  21b
K151E/E229K 0  0
E229K 58  9
a Invasion was measured using a standard gentamycin protection assay with S. flex-
neri SF622 making wild-type IpaD having 74  6 colonies per well (n  3). The
normal centrifugation step was omitted to avoid the loss of subtle differences in
invasion capacity.
b Indicates a statistical difference in the presented values (p	 0.01) using a Student’s
t test.
TABLE 2
Examination of the numbers of Shigella with IpaD or IpaB on the








Wild-type   
 d  (100%)e
ipaD null   
  
S158A   
  / (70%)
K151E   
   (100%)
K151E/E229K  / 
 / / (	20%)
E229K   
  (80%) / (20%)
a The number of bacteria having specific proteins on their surface was determined
by immunofluorescence staining of the bacteria as described under “Experimental
Procedures.” In each case more than 10 representative fields were examined with
at least 20 bacteria per field.
b IpaD stainingwaswithmonoclonal antibodies (16F8) prepared in the laboratory of
Dr. E. V. Oaks with rabbit anti-mouse IgG labeled with Alexa 488 dye as the
secondary antibody.
c IpaB staining was with rabbit antisera generated against IpaB in the laboratory of
Dr. E. V. Oaks with mouse anti-rabbit IgG labeled with Alexa 568 dye as the
secondary antibody.
d Changes in the intensity of perceived labeling (independent of the percentage of
cells stained) are estimated relative to SF622 expressing wild-type ipaD grown in
the absence of deoxycholate. Increased apparent labeling is shown with  or
.
e In samples where only a limited number of bacteria are stained for a given protein,
the approximate percentage of cells showing fluorescence staining as indicated by
the values given in parentheses.
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IpaDK151E, the numbers of bacteria possessing IpaD on the
surface is similar to that seen for wild-type bacteria in the
absence of deoxycholate (Table 2). There did, however, seem
to be a greater than normal intensity of IpaD staining on the
surface of these bacteria after deoxycholate was added while
having at least wild-type levels of IpaB. For the double mu-
tant IpaDK151E/E229K, 	20% of the bacteria appeared to have
IpaD on the bacterial surface in the absence or presence of
deoxycholate (Table 2). Perhaps more importantly, only a very
small number of bacteria have visible IpaB appear on their sur-
faces after deoxycholate addition (Table 2). This behavior is
distantly similar to that of the ipaB nullmutant strain S. flexneri
SF620 where IpaD is lost from the Shigella surface with deoxy-
cholate addition (11). The secretion profile for this mutant also
resembles that seen for SF620 with greatly elevated levels of
IpaB and IpaC in the overnight culture supernatants (data not
shown). Little IpaD, however, is seen here despite the fact that
these cells make normal levels of IpaD based on Western blot
analysis (data not shown). On the other hand, IpaDE229K
behaved essentially like wild-type bacteria with respect to IpaD
surface localization (Table 2), whereas only a fraction of these
bacteria had IpaB on their surfaces after the addition of deoxy-
cholate. It is interesting that IpaDS158A was less invasive than
IpaDE229K because the former appeared to only be somewhat
attenuated in its response to deoxycholate (Table 2), whereas
IpaDE229K appeared to be more dysfunctional in how it
responded to the presence of deoxycholate.
Monitoring the Ability for FITC-deoxycholate to Bind to Dif-
ferent Recombinant IpaD Mutant Proteins—Because there are
alterations in the function of IpaD when certain amino acids
thought to be involved in deoxycholate binding are changed, we
tested selected mutants to determine whether the binding of
FITC-deoxycholate to the purified mutants could be detected.
Becausemutations at Lys-151, Glu-229, and Ser-158 resulted in
the most significant changes in Shigella invasiveness, these
mutant forms of IpaD were targeted for purification and anal-
ysis of FITC-deoxycholate binding by FP (Fig. 6). Although
IpaDS158A gave rise to the largest decrease in Shigella invasive-
ness, it still bound FITC-deoxycholate although the apparent kd
was increased slightly (Fig. 6). This was not further altered by
simultaneously introducing mutations Q165A and Q162A,
which is consistent with invasion data showing that these addi-
tionalmutations do not further negatively affect the entry proc-
ess (Fig. 6 and Table 1). IpaDK151E likewise had a slightly higher
apparent kd value relative to wild-type protein, suggesting that
its dramatic positive effect on invasiveness is not due to
increased affinity for deoxycholate. Interestingly, IpaDE229K
was greatly reduced in its ability to bind FITC-deoxycholate,
which may correlate with the in vivo observation that it may
have a major defect in recruiting IpaB to the bacterial surface
(Table 2). Although this mutation is not in the putative deoxy-
cholate binding pocket, because Glu-229 is proposed to be
involved in a salt bridge with Lys-151, a conformational change
in IpaD may have occurred resulting in a decreased affinity for
deoxycholate and therefore preventing the recruitment of IpaB
to the bacterial surface.
DISCUSSION
The TTSS is an essential determinant for Shigella virulence
because it promotes invasion of the cells of the human intestine.
It has been recently shown that the essential virulence protein
IpaDworks primarily as a TTSA needle tip protein (9) with bile
salts acting as environmental signals for the stable recruitment
of IpaB onto the Shigella needle tip complex (11). In this study,
we show that the bile salt deoxycholate binds directly to IpaD
and this interaction can be studied in detail using established in
vitro analyses. Although it is not knownwhether other environ-
mental small molecules, especially those within the colonic
submucosa, can have a similar effect on the Shigella TTSA tip
complex composition, it is almost certain that bile salts elicit an
effect on the Shigella TTSA as this pathogen traverses the
human gastrointestinal tract. Consistent with the prior obser-
vation that different bile salts can influence Shigella virulence
functions (15) and participate in the recruitment of IpaB to
the TTSA needle tip (11), other bile salts were competitive for
the binding of FITC-deoxycholate by IpaD. One bile salt deriv-
ative (dehydrocholate), however, was not competitive. This bile
salt also fails to induce the recruitment of IpaB to the Shigella
surface (data not shown). This implicates the presence and
position of hydroxyl groups on deoxycholate with having a role
in interacting with specific amino acid side chains on IpaD.
It is intuitively attractive that the Salmonella homologue of
IpaD (SipD) also binds FITC-deoxycholate in vitro, because
both organisms are enteric pathogens, whereas BipD from the
systemic or pulmonary pathogenB. pseudomallei does not. Yet,
when expressed in S. flexneri SF622 (the ipaD null mutant),
BipD localizes to the MxiH needle tip (10, 38) as would be pre-
dicted for SipD as well, because all three are nearly identical at
their C termini at the sequence level, which is the region of IpaD
implicated in anchoring it to the needle (9).Whendeoxycholate
is added, however, BipD is lost from the SF622 needle tip as was
seen for IpaD when deoxycholate was added to the S. flexneri
ipaB null strain SF620 (10). Therefore, if IpaB cannot associate
FIGURE 6. The binding of FITC-deoxycholate to different IpaD site-spe-
cific mutants. Titration of 50 nM FITC-deoxycholate with increasing concen-
trations of protein was used to compare the binding properties of different
IpaD site-specific mutants. The proteins used were wild-type IpaD (closed
circles), IpaDE229K (open circles), IpaDS158A/Q162A/Q165A (closed triangles),
IpaDS158A (open triangles), and IpaDK151E (closed squares). The average starting
FP value for FITC-deoxycholate in these experiments was about 35 mP units
(n  3).
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with the needle tip, the tip protein, which may have undergone
a conformational change in response to the environmental sig-
nal (see IpaDE229K), is unable to maintain its association with
the needle tip and is thus released. Thus, the inability to grasp
IpaB probably stems from sequence differences at positions
other than the C terminus of the tip proteins. More impor-
tantly, however, this suggests that BipD has the information
within its structure needed to bind deoxycholate, but that the
unusual stability and complexity of its N-terminal domain (10,
17)may block deoxycholate binding in vitro, whereas the BipD-
MxiH needle tip complex is able to recognize the presence of
deoxycholate. This once again implicates the central coiled-coil
of these tip complex proteins in the recognition of environmen-
tal smallmolecules. It was recently reported by Zhang et al. (31)
that the N terminus of IpaD may be displaced by MxiH when
the former assumes a stable position at the Shigella TTSA nee-
dle tip. It is thus possible that the BipD N-terminal globular
domain is similarly displaced, which allows it to take up the
observed position at the MxiH needle tip. Based upon molecu-
lar modeling and docking simulations, it is possible that tip-
associated BipD has a newly created deoxycholate binding site
that does not exist for full-length BipD alone in solution.
Mutational analyses focused on a region between Lys-151
and Ser-158 and the corresponding putative salt bridge partner
at Glu-229. The effects of some of the mutations were subtle,
whereas others were quite substantial, both positively and neg-
atively for the pathogen. Based on molecular modeling,
IpaDS158A wasmade and invasion was reduced by 80% but IpaB
surface localization was only reduced by 20%. If, however, the
efficiency or rate of IpaBmobilization is severely restricted, this
could cause the significant reduction in invasion that is
observed. Another mutant near the putative deoxycholate
binding site, IpaDK151E, gave rise tomore than a 4-fold increase
in Shigella invasiveness. Based on FP IpaDK151E does not greatly
alter deoxycholate binding, which gives indirect evidence
(along with the other two mutants) that the salt bridge may in
fact be real. Because previous reports have proposed that Lys-
151 could be involved in salt bridge formation with Glu-229 on
the adjacent IpaD monomer within the IpaD needle tip com-
plex (10), the double mutant IpaDK151E/E229K was made but it
rendered Shigella entirely noninvasive. This could not be
explained in part by IpaDE229K because this mutant was still
invasive, but at reduced levels relative to Shigella expressing
wild-type ipaD. This does suggest that Glu-229 and Lys-151
work cooperatively, but there is not an obvious mechanism to
account for the observed effects of the double mutation. Inter-
estingly, IpaDE229K was more compromised in FITC-deoxy-
cholate binding in vitro than any of the mutations directed at
the identified deoxycholate pocket. Again, it is possible that this
residue is critical for dynamic structural changes in IpaD that
are part of the deoxycholate-signaling process.
In light of the data concerning the K151E and E229K muta-
tions, it must be acknowledged that introducingmutations that
reverse local charges can influence more than a protein-ligand
interaction. It is certainly possible that such mutations could
induce localized or even distant changes in protein conforma-
tion that could drastically alter protein function. Such an event
could account for the positive and negative effects, respectively,
that the K151E and E229K mutations have on the invasion
function of IpaD. In fact, the observation that recombinant
IpaDE229K appears to have a slightly reduced affinity for deoxy-
cholate could be explained by a mutation-induced change in
the conformation of the deoxycholate binding pocket. This
would also be consistent with the data presented in Table 2 for
this mutant. In the case of IpaDK151E/E229K the complete loss of
the invasion function of IpaD, the reducedmaintenance of IpaD
on the Shigella surface, and the altered ability for deoxycholate
to recruit IpaB to the bacterial surface aremost easily explained
by proposing that IpaD has undergone a conformational
change in response to the double mutation.
Taken together, the biochemical, mutagenesis, and compu-
tational data support a model in which deoxycholate interacts
with IpaD, the ShigellaTTSAneedle tip protein, to promote the
stable recruitment and retention of IpaB to form a ternary com-
plex with IpaD and MxiH atop the Shigella TTSA needle tip.
Although unequivocal evidence of the residues required for
deoxycholate binding will necessitate detailed structural analy-
ses, mutational studies clearly show that amino acid residues
within the putative deoxycholate binding pocket appear to have
roles in: 1) IpaB recruitment to the TTSA needle tip; 2) the
strength of the IpaD-deoxycholate interaction; and 3) Shigella
invasion efficiency for cultured cells. The biochemical, struc-
tural, and docking data presented here and in preceding works
(10, 11, 31) provide a first step toward understanding how the
Shigella TTSS is involved in responding to its environment.
Furthermore, because the molecular structures of IpaD and
MxiH have been solved, the use of molecular modeling and
docking simulations can now provide a basis for the rational
design of drugs targeting the Shigella TTSA. The finding that
BipD at the MxiH needle tip is affected by deoxycholate addi-
tion whereas BipD does not interact with deoxycholate in vitro
suggests that anti-infective agents that block Shigella TTSA
functionmay have broad spectrum effects that could also influ-
ence other type III secretion systems.
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The synthesis of  (R)-4-((3R,5R,8R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-
dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-N-(6-(3-(3',6'-dihydroxy-3-oxo-
3H-spiro[isobenzofuran-1,9'-xanthene]-5-yl)thioureido)hexyl)pentanamide (4, DOC-FITC) is 
shown in Scheme 1 and the experimental details and spectral data are given in the Experimental 
Section.  Figure S1 is the high resolution mass spectrum of 4.  
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a.  1, EDCI, HOBT, Boc-1,6-hexanediamine, DMF, 24 h. 75%.  b.  4M HCl, 1,4-dioxane, 1h, 





















aminium (3).  A solution of deoxycholic acid (DOC, 503 mg, 1.28 mmol), hydroxybenzotriazole 
(HOBT, 173 mg, 1.28 mmol), and 1-ethyl-3-(3-dimethyl aminopropyl) carbodiimide 
Supplemental Materials 
 2 
hydrochloride (EDC, 368 mg, 1.92 mmol) in 10 ml of DMF was stirred for 30 min to ensure 
complete dissolution.  While stirring, tert-butyl-6-aminohexylcarbamate (277 mg, 1.28 mmol) in 
5 ml DMF was slowly added over 5 minutes.  The reaction proceeded for 22 h under ambient 
conditions.  After this time, the solution was diluted with ethyl acetate and 100 ml of water was 
added.  An extraction of the organic layer then was performed, followed by addition of 
anhydrous magnesium sulfate.  After solvent removal, 15 ml of 4 M HCl in 1, 4-dioxane was 
added.  Stirring of this solution, under ambient conditions, occurred for 1 h.  Excess solution was 
removed under reduced pressure for 2 days.  Amine 3 was obtained as a white, adhesive 
precipitate, 456 mg (75%).  1H NMR (400 MHz, MeOD) d 7.98 (s,1H), 3.61 (m, 2H), 3.19 (t, 
2H), 2.94 (t, 2H), 2.31 (m, 4H), 1.61-1.33 (m, 31H), 1.23 (s, 3H), 0.99 (s, 3H), 0.88 (s, 3H).  13C 
NMR (125 MHz, MeOD), δ 177.97, 74.17, 72.68, 48.83, 48.15, 47.72, 43.75, 40.89, 40.80, 
37.61, 37.44, 37.34, 37.13, 36.57, 35.46, 34.98, 33.66, 32.08, 31.22, 30.96, 30.09, 30.01, 28.87, 
28.63, 27.49, 27.15, 25.02, 23.86, 17.74, 13.33 cm-1  IR (KBr):  3584, 3226, 2950, 2846, 1657, 
1569, 1448, 1419, 1390, 1340, 1157, 1100, 1062, 1016 cm-1.  HRMS (M+):  Calc'd for 
C30H55N2O3






















spiro[isobenzofuran-1,9'-xanthene]-5-yl)thioureido)hexyl)pentanamide (4).  A solution of 3 
(238 mg, 0.484 mmol) and fluorescein-4-isothiocyanate (FITC, 226 mg, 0.581 mmol) in 20 ml of 
MeOH was stirred for 30 min.  While stirring at 0 oC, triethylamine (TEA, 67 mL (0.484 mmol) 
was added over a period of 5 minutes.  The reaction proceeded under ambient conditions for 16 
h.  Solvent removal under reduced pressure followed to yield a dark red/brown precipitate.  Flash 
column chromatography (100% ethyl acetate, then 1:1 ethyl acetate/acetone, then 1:1 
acetone/methanol furnished 227 mg of 4 (53%) as a yellow waxy precipitate. 1H NMR (400 
MHz, MeOD) δ 8.22 (s, 1H), 7.76 (m, 2H), 7.16 (d, 1H), 6.68 (m, 3H), 6.55 (m, 3H),  3.61 (m, 
2H), 3.19 (t, 2H), 2.94 (t, 2H), 2.31 (m, 4H), 1.61-1.33 (m, 31H), 1.23 (s, 3H), 0.99 (s, 3H), 0.88 
(s, 3H).  13C NMR (125 MHz, MeOD), δ 182.84, 176.96, 171.68, 154.70, 142.76, 131.75, 
130.66, 126.28, 126.11, 126.02, 120.22, 118.83, 114.35, 112.29, 112.04, 74.17, 72.68, 48.83, 
48.15, 47.72, 43.75, 40.89, 40.80, 37.58, 37.34, 36.96, 36.58, 35.45, 34.96, 34.38, 33.60, 31.22, 
30.49, 30.05, 30.00, 29.69, 28.88, 28.55, 27.75, 27.62, 25.03, 23.91,17.83, 13.43.  9.38.  IR 
(KBr):  3580, 3278, 2933, 2856, 1757, 1712, 1614, 1587, 1504, 1452, 1365, 1334, 1220, 1180, 
1118, 1081, 871, 850, 786, 711, 673 cm-1.  HRMS (M + H):  Calc'd for C51H65N3O8S:  880.4571.  




Figure S1.  MS Analysis of FITC-labeled deoxycholic acid (4, DOC-FITC).  This figure 
shows a high resolution mass spectrum of FITC-DOC.  The spectrum was obtained using a 
Waters LCT Electrospray, Time of Flight instrument in positive ion mode, with leucine 
enkephalin as the internal reference (MW = 555.63).  The signal at m/z 880.4613 indicates the 



























Table S1.  Primer sequences for generating IpaD site-specific mutants.  The forward and 
reverse primers are shown for the introduction of mutations in IpaD as described in Methods.  
 
K72A – Use SpeI site at 217 
D155f – GAG AGA GAG ACT AGT CTA GAA GAA ATA GCA TTA CAT 
D156r – GAG AGA GAG ACT AGT TGC AGT CAA CGT TTT TTG TGA AAG 
 
L75S/A79S – Use SpeI site at 217 
D157f -  GAG AGA GAG ACT AGT TCA GAA GAA ATA TCA TTA CAT TCA TCT CAG 
ATT A 
D158r – GAG AGA GAG ACT AGT TTT AGT CAA CGT TTT TTG TGA AAG 
 
K72A/L75S/A79S 
D157f & D156r 
 
E154A/H155A – Makes a NotI site 
D159f – GAG AGA GAG GCG GCC GCC GTT AGT TCA TAT ACT C 
D160r – GAG AGA GAG GC GGC CGC ATA TAC TTT CAG ATA CTG TTC 
 
S158A – Makes a NheI site 
D161f – GAG AGA GAG GCT AGC TAT ACT CAA ATG TAT CAA GAT T 
D162r- GAG AGA GAG GCT AGC TTC GGC TAG TTC ATA TAC TT 
 
S158A/H155A – Use the NheI site 
D161f 
D163r – GAG AGA GAG GCT AGC TTC GGC TGC TTC ATA TAC TT 
 
S158A/H155A/E154A - Use NheI site 
D161f 
D164r - GAG AGA GAG GCT AGC TTC GGC TGC TGC ATA TAC TTT CAG ATA CTG 
TT 
 
S158/T161A – Use NheI site 
D165f – GAG AGA GAG GCT AGC TAT GCT CAA ATG TAT CAA GAT TTT AG 
D162r 
 
S158/T161A/Q162A – Use NheI site 
D166f – GAG AGA GAG GCT AGC TAT GCT GCA ATG TAT CAA GAT TTT AG 
D162r 
 
S158/Q162A – Use NheI site 
D167f – GAG AGA GAG GCT AGC TAT ACT GCA ATG TAT CAA GAT TTT AGC GCT 
D162r 
 
S158/Q162A/Q165A – use the NheI site  
Supplemental Materials 
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E229K – Use MfeI 
D173 - GAGAGAGAGCA ATT GGC AAG GTA TCT CAA AAA AA  
D174 - GAGAGAGAGC AAT TGT TCC ACC TAA TTT TGT AAG CCA TTT ATT TGC 
TTG   
 
K151E – Use XhoI 
D126 – GAG AGA CTC GAG GTA TAT GAA CAT GCC GTT A 
D127 – GAG AGA CTC GAG ATA CTG TTC ATT AAT ATC A 
 






Figure S2. Transmission electron micrographs of immunogold-labeled IpaD and IpaB at 
the S. flexneri TTSA needle tip.  Free TTSA needles (left panel) or S. flexneri-associated 
needles (right panel) were immunolabeled with secondary gold-labeled antibodies. For the 
micrographs shown, the samples were treated with monoclonal anti-IpaD IgG/5-nm gold-labeled 
goat anti-mouse F(ab’)2 and/or rabbit anti-IpaB IgG/10-nm gold-labeled goat anti-rabbit F(ab’)2. 
The samples were then negatively stained with uranyl acetate.  The arrows indicate labeling of 
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